YUHSpace: Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC

YUHSpace

BROWSE

0 134

Cited 4 times in

Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC

Authors: Sun Min Lim ; Jii Bum Lee ; Byoung Chul Cho

Citation: JOURNAL OF THORACIC ONCOLOGY, Vol.19(3) : 376-379, 2024-03

Journal Title: JOURNAL OF THORACIC ONCOLOGY

ISSN: 1556-0864

Issue Date: 2024-03

MeSH: Acrylamides* ; Aniline Compounds / pharmacology ; Aniline Compounds / therapeutic use ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; ErbB Receptors / genetics ; ErbB Receptors / therapeutic use ; Humans ; Indoles* ; Lung Neoplasms* / drug therapy ; Mutation ; Protein Kinase Inhibitors / therapeutic use ; Pyrimidines / therapeutic use

Full Text: https://www.sciencedirect.com/science/article/pii/S1556086423024127

DOI: 10.1016/j.jtho.2023.12.007

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Lee, Jii Bum(이기쁨) https://orcid.org/0000-0001-5608-3157
Lim, Sun Min(임선민)
Cho, Byoung Chul(조병철) https://orcid.org/0000-0002-5562-270X

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/200575

사서에게 알리기

Show full item record Find it @ YMLIB

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

License

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links